Indication: Gastric Cancer
A randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC)
Sub-indication: Gastrointestinal Cancer
Study Type: Drug Study
Principal Investigator: Michael Driscoll, M.D.Norton Cancer Institute
Sponsor: Sponsor: Seattle Genetics, Inc
Learn more at ClinicalTrials.gov
Email for more information: GI-NCIResearch@nortonhealthcare.org